Biosimilars and Future Biotherapeutics

Artificial Intelligence and Digital Tools in Biotherapeutics

The integration of artificial intelligence (AI) and digital tools in biotherapeutics is revolutionizing how biologic drugs, including biosimilars and innovative biologics, are researched, developed, manufactured, and administered. Traditionally, the development of biotherapeutics has been a lengthy, complex, and expensive process, involving high levels of uncertainty, especially in early discovery and clinical translation. AI technologies—ranging from machine learning and deep learning to natural language processing and predictive analytics—are now addressing these challenges by enabling faster, more accurate decision-making across the biotherapeutic value chain. In drug discovery, AI algorithms are used to screen vast libraries of compounds, predict protein–protein interactions, and identify potential therapeutic targets. By analyzing massive datasets from genomic, proteomic, and clinical sources, AI can uncover novel disease pathways and biomolecular relationships, significantly accelerating lead identification and optimization for monoclonal antibodies, fusion proteins, and other biotherapeutics. One of the most transformative applications of AI in biotherapeutics is in protein structure prediction and design. Tools like AlphaFold, developed by DeepMind, have demonstrated the ability to predict complex protein folding patterns with remarkable accuracy, aiding in the design of biologics with improved stability, specificity, and reduced immunogenicity.